New hope to stop transplanted kidneys from scarring and failing

This study is testing whether adding a drug called belumosudil to standard anti-rejection medications can prevent scarring in newly transplanted kidneys. Researchers want to see if blocking a specific biological pathway can reduce structural damage that often leads to transplant failure over time. The trial involves 40 recent kidney transplant recipients who will take either the study drug or a placebo for one year while continuing their regular immunosuppression therapy.